Business Context and Reporting Period
This Form 6-K filing by Smith & Nephew plc, dated May 21, 2025, serves as a notification and public disclosure of transactions by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them. The report is made in accordance with the UK Market Abuse Regulation.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details share transactions related to executive compensation.
- Transaction Date: May 20, 2025
- Transaction Type: Vesting of Performance Share Plan and Conditional Share awards under the Global Share Plan 2020, followed by sales to cover tax liabilities.
- Share Price: £10.875359 per share.
- Performance Metric: Performance Share Plan awards vested at 59.35% of target.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records the execution of pre-existing equity incentive plans for specific executives.
Management Commentary and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a statutory disclosure of share movements.
Executive Share Transactions Summary
| Executive Name | Position | Total Vested | Sold (Tax) | Retained |
|---|---|---|---|---|
| Deepak Nath | Chief Executive Officer | 83,938 | 34,477 | 49,461 |
| Craig Gaffin | President, Global Orthopaedics | 1,551 | 379 | 1,172 |
| Elga Lohler | Chief HR Officer | 20,174 | 8,026 | 12,148 |
| Vasant Padmanabhan | President, R&D and ENT | 19,626 | 8,708 | 10,918 |
| Rohit Kashyap | President, Advanced Wound Management | 11,949 | 2,920 | 9,029 |
Key Facts for Investor Verification
- Verify the 59.35% vesting rate for Performance Share Plan awards against the company's stated performance targets for the relevant period.
- Confirm the share price of £10.875359 aligns with the market price on May 20, 2025.
- Note that all sales reported were executed specifically to cover tax obligations arising from the vesting events.
- Recognize that this filing provides no insight into the company's operational or financial health for the period.